Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

Next Day Disclosure Return 2021-11-26
GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME 2021-11-25
VOLUNTARY ANNOUNCEMENT - KN035 (ENVAFOLIMAB) OBTAINED MARKETING APPROVAL IN CHINA FROM NMPA 2021-11-25
VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY NMPA FOR A PHASE III CLINICAL TRIAL OF KN046 FOR THE TREATMENT OF ADVANCED PDAC 2021-11-23
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021 2021-11-04
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF COMMERCIAL OFFICER 2021-11-02
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE II/III CLINICAL TRIAL OF KN046 IN COMBINATION WITH LENVATINIB FOR THE TREATMENT OF PD-(L)1 REFRACTORY ADVANCED NSCLC 2021-10-28
GRANT OF SHARE OPTIONS 2021-10-25
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN A PHASE III CLINICAL TRIAL OF KN046 IN COMBINATION WITH CHEMOTHERAPY IN THE TREATMENT OF ADVANCED UNRESECTABLE OR METASTATIC SQUAMOUS NSCLC 2021-10-15
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2021 2021-10-08

14 15 16 17 18 19 20